Amedica (NASDAQ: AMDA) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it contrast to its competitors? We will compare Amedica to similar businesses based on the strength of its earnings, risk, analyst recommendations, institutional ownership, valuation, profitability and dividends.
Risk and Volatility
Amedica has a beta of -2.08, suggesting that its stock price is 308% less volatile than the S&P 500. Comparatively, Amedica’s competitors have a beta of 0.79, suggesting that their average stock price is 22% less volatile than the S&P 500.
This is a breakdown of current ratings and target prices for Amedica and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Amedica presently has a consensus target price of $60.00, suggesting a potential upside of 1,571.31%. As a group, “Medical Devices & Implants” companies have a potential upside of 34.92%. Given Amedica’s higher probable upside, equities analysts clearly believe Amedica is more favorable than its competitors.
Valuation and Earnings
This table compares Amedica and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Amedica||$15.23 million||-$16.59 million||-1.86|
|Amedica Competitors||$1.67 billion||$207.58 million||56.87|
Amedica’s competitors have higher revenue and earnings than Amedica. Amedica is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
62.5% of Amedica shares are owned by institutional investors. Comparatively, 54.4% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 0.1% of Amedica shares are owned by insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Amedica and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Amedica competitors beat Amedica on 9 of the 13 factors compared.
Amedica Company Profile
Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States, Europe and Brazil for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride-based spinal fusion products, it markets a line of non-silicon nitride spinal surgery products, which allows the Company to provide surgeons and hospitals with a solution for spinal procedures. Its Valeo interbody spinal fusion devices include Anterior Lumbar, Posterior Lumbar, Oblique Lumbar, Transforaminal Lumbar, Lateral Lumbar, Cervical and Corpectomy.
Receive News & Ratings for Amedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica and related companies with MarketBeat.com's FREE daily email newsletter.